2022 World Conference on Lung Cancer (ePosters)-EP08.01-103. Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

EP08.01-103. Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of combining anlotinib with programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors as a second-line and subsequent therapy for advanced small-cell lung cancer (SCLC). The study included 40 patients who received this combination therapy at Shanghai Chest Hospital between November 2016 and November 2020.<br /><br />The results showed that among the patients who received anlotinib plus PD-1/PD-L1 inhibitors, the objective responses included progressive disease in 20.0% of patients, stable disease in 65.0%, partial response in 15.0%, and complete response in 0%. The disease control rate was 80.0%. The median progression-free survival was 3.40 months, and the median overall survival was 8.20 months.<br /><br />The most pronounced adverse events reported were fatigue and decreased appetite. Two patients discontinued the combined therapy due to intolerable adverse events, but the remaining patients who experienced tolerable adverse events were able to complete the therapy or were still undergoing the combination therapy.<br /><br />The study concludes that the combination of anlotinib and PD-1/PD-L1 blockade shows promising efficacy and safety as a second-line and subsequent therapy for SCLC. The authors declare no conflicts of interest, and the study was supported by the Science and Technology Innovation Program of Shanghai and Nurture projects for basic research of Shanghai Chest Hospital.

Asset Subtitle

Lian Yu

Meta Tag

Speaker Lian Yu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

anlotinib

programmed cell death protein 1

PD-1

programmed cell death-ligand 1

PD-L1

small-cell lung cancer

efficacy

safety

combination therapy

adverse events